Arushi Singh1, Nadia El Hangouche2, Katherine McGee1, Fei-Fei Gong2, Robert Lentz3, Joseph Feinglass1, Nausheen Akhter2. 1. Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 2. Division of Cardiovascular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3. Division of Hematology and Oncology, University of Colorado School of Medicine, University of Colorado, Aurora, CO, USA.
Abstract
BACKGROUND: Ibrutinib is associated with atrial fibrillation (AF), though echocardiographic predictors of AF have not been studied in this population. We sought to determine whether left atrial (LA) strain on transthoracic echocardiography could identify patients at risk for developing ibrutinib-related atrial fibrillation (IRAF). METHODS: We performed a retrospective review of 66 patients who had an echocardiogram prior to ibrutinib treatment. LA strain was measured with TOMTEC Imaging Systems, obtaining peak atrial longitudinal strain (PALS) and peak atrial contraction strain (PACS) on 4-chamber and 2-chamber views. Statistical analysis was performed with chi-square analysis, t test, or binomial regression analysis, with a P-value < .05 considered statistically significant. RESULTS: Twenty-two patients developed IRAF (33%). Age at initiation of ibrutinib was significantly associated with IRAF (65.1 years vs 74.1 years, P = .002). Mean ibrutinib dose was lower among patients who developed IRAF (388.2 ± 121.7 vs 448.6 ± 88.4, P = .025). E/e' was significantly higher among patients who developed IRAF (11.5 vs 9.3, P = .04). PALS was significantly lower in patients who developed AF (30.3% vs 36.3%, P = .01). On multivariate regression analysis, age, PALS, and PACS were significantly associated with IRAF. On multivariate regression analysis, only PACS remained significantly associated with IRAF while accounting for age. CONCLUSIONS: Age, ibrutinib dose, E/e', and PALS on pre-treatment echocardiogram were significantly associated with development of IRAF. On multivariate regression analyses, age, PALS, and PACS remained significantly associated with IRAF. Impaired LA mechanics add to the assessment of patients at risk for IRAF.
BACKGROUND: Ibrutinib is associated with atrial fibrillation (AF), though echocardiographic predictors of AF have not been studied in this population. We sought to determine whether left atrial (LA) strain on transthoracic echocardiography could identify patients at risk for developing ibrutinib-related atrial fibrillation (IRAF). METHODS: We performed a retrospective review of 66 patients who had an echocardiogram prior to ibrutinib treatment. LA strain was measured with TOMTEC Imaging Systems, obtaining peak atrial longitudinal strain (PALS) and peak atrial contraction strain (PACS) on 4-chamber and 2-chamber views. Statistical analysis was performed with chi-square analysis, t test, or binomial regression analysis, with a P-value < .05 considered statistically significant. RESULTS: Twenty-two patients developed IRAF (33%). Age at initiation of ibrutinib was significantly associated with IRAF (65.1 years vs 74.1 years, P = .002). Mean ibrutinib dose was lower among patients who developed IRAF (388.2 ± 121.7 vs 448.6 ± 88.4, P = .025). E/e' was significantly higher among patients who developed IRAF (11.5 vs 9.3, P = .04). PALS was significantly lower in patients who developed AF (30.3% vs 36.3%, P = .01). On multivariate regression analysis, age, PALS, and PACS were significantly associated with IRAF. On multivariate regression analysis, only PACS remained significantly associated with IRAF while accounting for age. CONCLUSIONS: Age, ibrutinib dose, E/e', and PALS on pre-treatment echocardiogram were significantly associated with development of IRAF. On multivariate regression analyses, age, PALS, and PACS remained significantly associated with IRAF. Impaired LA mechanics add to the assessment of patients at risk for IRAF.
Authors: Sarju Ganatra; Ajay Sharma; Sachin Shah; Ghulam M Chaudhry; David T Martin; Tomas G Neilan; Syed Saad Mahmood; Ana Barac; John D Groarke; Salim S Hayek; Saurbha Dani; David Venesy; Richard Patten; Anju Nohria Journal: JACC Clin Electrophysiol Date: 2018-08-29
Authors: Joe-Elie Salem; Ali Manouchehri; Marie Bretagne; Bénédicte Lebrun-Vignes; John D Groarke; Douglas B Johnson; Tao Yang; Nishitha M Reddy; Christian Funck-Brentano; Jennifer R Brown; Dan M Roden; Javid J Moslehi Journal: J Am Coll Cardiol Date: 2019-10-01 Impact factor: 24.094
Authors: Julie R McMullen; Esther J H Boey; Jenny Y Y Ooi; John F Seymour; Michael J Keating; Constantine S Tam Journal: Blood Date: 2014-12-11 Impact factor: 22.113
Authors: Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt Journal: Eur Heart J Cardiovasc Imaging Date: 2015-03 Impact factor: 6.875
Authors: Giuseppe Boriani; Paolo Corradini; Antonio Cuneo; Anna Falanga; Robin Foà; Gianluca Gaidano; Paolo Prospero Ghia; Maurizio Martelli; Roberto Marasca; Massimo Massaia; Francesca Romana Mauro; Giorgio Minotti; Stefano Molica; Marco Montillo; Antonio Pinto; Alessandra Tedeschi; Umberto Vitolo; Pier Luigi Zinzani Journal: Hematol Oncol Date: 2018-03-07 Impact factor: 5.271
Authors: Jakub Strzelczyk; Piotr Kalinowski; Krzysztof Zieniewicz; Cezary Szmigielski; Michał Byra; Grzegorz Styczyński Journal: Obes Surg Date: 2021-09-22 Impact factor: 4.129